Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Attachment |
| Title | 25467016 |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/25467016 |
| Accessed | 2018/05/23 - 14:14:19 |
| Date Added | 2018/11/14 - 15:25:02 |
| Date Modified | 2018/11/14 - 15:25:02 |
| Parent item | Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de